BioCorRx Enters Confidentiality Agreement with Federal

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Nov 15, 2017 at 10:00 AM 465

BioCorRx Enters Confidentiality Agreement with Federal Government Research Institute; Plans to Attend FDA Meeting for Naltrexone Implant

ANAHEIM, CA--(Marketwired - Nov 15, 2017) - BioCorRx, Inc. ( OTCQB : BICX ) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addiction, today announced that it has entered into a confidentiality agreement with the National Institute on Drug Abuse (NIDA), a United States federal-government research institute whose mission is "to advance science on the causes and consequences of drug use and addiction and to apply that knowledge to improve individual and public health." The purpose of the agreement is to share confidential information and potentially collaborate on further research, development and commercialization of the Company's therapies and programs for opioid use disorder.

According to the 2016-2020 NIDA Strategic Plan, one of the goals is to "develop new and improved treatments to help people with substance use disorders achieve and maintain a meaningful and sustained recovery." More information about NIDA's Strategic Plan can be found at: https://www.drugabuse.gov/about-nida/strategi...treatments .

In a meeting held by BioCorRx and its development team with NIDA via teleconference on November 8, 2017, NIDA agreed to participate as an observer at the pre-IND meeting for BICX102 with the FDA, which is scheduled for January 24, 2018. BICX102 is the Company's sustained release naltrexone implant being developed for opioid and alcohol use disorders. Brady Granier, CEO of BioCorRx, is also scheduled to meet with NIDA in Washington, DC next week on November 21st for follow up discussions and technical advice on BICX102, as well as to discuss opportunities with BioCorRx's Cognitive Behavioral Therapy (CBT) mobile application recently developed.

Brady Granier, CEO, President, and Director of BioCorRx, commented, "We are honored that NIDA has agreed to engage with us through this process. Our desire is to get this valuable treatment option to market as quickly as possible so that we can help those suffering from opioid use disorder, as well as those suffering from alcohol use disorder. The medical community and government entities have shown strong interest in our products and we have seen a high demand for an antagonist therapy that can last several months. We look forward to the next meeting with NIDA and for their attendance at our upcoming FDA meeting. We believe this naltrexone product can save many more lives if approved and becomes more widely accepted by payers."

About BioCorRx

BioCorRx, Inc. ( OTCQB : BICX ) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx, Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com .

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx, Inc. investors@BioCorRx.com 714-462-4880 Investor Relations: Crescendo Communications, LLC (212) 671-1020 x304 bicx@crescendo-ir.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

EFICYENT Ventures to Connect at Singapore FinTech Fest

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Novo's CagriSema Trials Show Promising Weight Loss

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...